The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
Related Posts
Consumer confidence surges as election nears, while job openings move lower
Consumers grew more optimistic heading into the contentious presidential election even as job openings hit multi-year lows.
CoreWeave opens at $39 per share after biggest U.S. tech IPO since 2021
CoreWeave received the most proceeds from a U.S. technology IPO since automation software maker UiPath went public in 2021.
S&P 500 futures slide as Nvidia shares tumble, traders await retail sales data: Live updates
Coming off a muted day for stocks, Wall Street investors looked ahead to more first-quarter earnings and a key retail sales report.